Target intelligence / Profile preview

Neisseria meningitidis group B recombinant protein antigen

Molecular classification
Bacterial surface protein, Adhesin (NadA), Lipoprotein (fHbp, NHBA), Vaccine antigen, Outer membrane protein
01

Overview

The "Neisseria meningitidis group B recombinant protein antigen" refers to a set of purified, genetically-engineered bacterial proteins used as antigenic components in vaccines against the group B strain of Neisseria meningitidis, a major cause of bacterial meningitis and sepsis. The most studied and widely-used recombinant antigens are factor H binding protein (fHbp), Neisserial adhesin A (NadA), and Neisserial heparin binding antigen (NHBA). These are found on the bacterial outer membrane, contribute to pathogenesis through immune evasion or cell adhesion, and are recognized by the human immune system, eliciting protective antibody responses when used in vaccines such as Bexsero. Recombinant protein antigen-based vaccines offer broad protection by including multiple conserved targets, and their efficacy depends on the conservation, surface expression, and immunogenicity of these proteins among circulating bacterial strains.

Other names
4CMenB vaccine protein antigensBexsero antigensNeisseria meningitidis group B vaccine recombinant proteinsNHBANadAfHbpfactor H binding proteinNeisseria adhesin ANeisseria heparin binding antigenGNA2132 (NHBA)GNA1870 (fHbp)GNA1994 (NadA)
02

Mechanism of action

Induction of bactericidal antibodies via complement-mediated killing (NHBA, NadA, fHbp); Immune memory generation (vaccination effect)

03

Biological functions

Host cell adhesion (NadA, NHBA)Complement evasion/serum resistance (fHbp, NHBA)Evasion of immune system (fHbp)Biofilm formation (NHBA)Immune response trigger (vaccine antigen activity)
04

Disease associations

Infection (bacterial meningitis, septicemia by Neisseria meningitidis group B)
05

Safety considerations

Potential for incomplete strain coverage due to antigenic diversityRare risk of strong local or systemic immune reaction (as with protein-based vaccines)
06

Interacting drugs

Bexsero (4CMenB vaccine)

1 more in the full profile.

07

Biomarkers

Surface expression levels of NHBA, NadA, fHbp for strain coverage predictionAntibody titers against these antigens (serological response)

Beyond the preview

Go deeper on Neisseria meningitidis group B recombinant protein antigen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neisseria meningitidis group B recombinant protein antigen.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call